Cashu | News | NVS

HomeWatchlistNewsSignalsPicks

DJI

-0.10%

SPX

-0.03%

IXIC

+0.13%

FTSE

+0.11%

N225

0.00%

AXJO

0.00%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest Novartis AG News

Assessing Intellia Therapeutics: Insights From 9 Financial Analysts

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

Feature Image for interests on Biotech, Briefs, Healthcare, Large Cap from benzinga.com

Sinotau Aims To Be Hong Kong's 'First Nuclear-medicine Stock'

Feature Image for interests on Asia, Biotech, Contributors, ETF from benzinga.com

Is Novartis Gaining or Losing Market Support?

Feature Image for interests on Bzi-Shorthist, Healthcare, Short Ideas, Short Sellers from benzinga.com

Where Incyte Stands With Analysts

Why Is Contact Lens Maker Cooper Companies Stock Trading Lower On Friday?

Feature Image for interests on Briefs, Expert Ideas, Financial Services, Health Care from benzinga.com

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

Feature Image for interests on Briefs, Fda, Health Care, Healthcare from benzinga.com

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews

Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks

Feature Image for interests on Baba, Benzinga, Consumer Cyclical, Etfs from benzinga.com

about 1 month ago

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

Feature Image for interests on Bdx, Benzinga, Biotech, Bmy from benzinga.com

about 1 month ago

Latest Cashu News

Novartis AG Navigates Complex Biotech Landscape Amidst Competitive Pressures from Intellia

Novartis AG Reports Positive Phase 3B Results for PNH Treatment Fabhalta

Novartis AG Advances PNH Treatment with Promising Fabhalta Phase 3B Study Results

Stocks

Health Care

nvs

Novartis AG

NVS

-0.42 (-0.37%)

115.985

USD

At close at Jun 18, 20:38 UTC